Back to Browse Journals » Therapeutics and Clinical Risk Management » Volume 4 » Issue 4

Sevelamer carbonate in the treatment of hyperphosphatemia in patients with chronic kidney disease on hemodialysis

Authors Vincenzo Savica, Domenico Santoro, Paolo Monardo, Agostino Mallamace, Guido Bellinghieri

Published Date September 2008 Volume 2008:4(4) Pages 821—826

DOI http://dx.doi.org/10.2147/TCRM.S3075

Published 1 September 2008

Vincenzo Savica1,2, Domenico Santoro1, Paolo Monardo2, Agostino Mallamace1, Guido Bellinghieri1

1Experimental and Clinic Department of Internal Medicine and Pharmacology, University of Messina, Italy; 2Nephrology and Dialysis Unit, Papardo Hospital, Messina, Italy

Abstract: Sevelamer carbonate is an anion exchange pharmaceutical, developed to improve on the performance of the non-absorbable, non-calcium, and metal-free phosphate binder sevelamer hydrochloride. Sevelamer carbonate is expected not to worsen metabolic acidosis, as previously reported during long-term treatment with sevelamer hydrochloride in hemodialysis (HD) patients. Carbonate is the alternate counterion to chloride on the sevelamer polymeric backbone, but the active poly(allylamine) responsible for phosphate (PO4) binding remains unaltered. Therefore, sevelamer carbonate is expected to reduce elevated serum phosphorus level, similarly to sevelamer hydrochloride. Sevelamers are prescribed in uremic HD patients to control hyperphosphatemia, but the carbonate has also been proposed for the treatment of chronic kidney disease (CKD) non-dialysis patients. Although hyperphosphatemia is regarded as a main contributor to increased mortality in the HD population because of cardiovascular calcification, metabolic acidosis has also been advocated as a major player in the increased mortality in this population, by engendering malnutrition, negative nitrogen balance, and inflammation. This paper reviews the evidence showing that sevelamer carbonate is as good as sevelamer hydrochloride in terms of hyperphosphatemia control in CKD, but with a better outcome in serum bicarbonate balance.

Keywords: chronic kidney disease, sevelamer carbonate, hyperphosphatemia, hemodialysis

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Readers of this article also read:

Impact of pharmacist interventions on drug-related problems and laboratory markers in outpatients with human immunodeficiency virus infection

Molino CGRC, Carnevale RC, Rodrigues AT, Visacri MB, Moriel P, Mazzola PG

Therapeutics and Clinical Risk Management 2014, 10:631-639

Published Date: 7 August 2014

Clinical significance of B7-H4 expression in matched non-small cell lung cancer brain metastases and primary tumors

Li ZY, Zhang XH, Chen Y, Guo JG, Sai K, Yang QY, Chen ZP, Mou YG

OncoTargets and Therapy 2013, 6:869-875

Published Date: 10 July 2013

Erratum

Sørensen HT, Friborg S, Rungby J, Christiansen JS, Vaag A, Beck-Nielsen H

Clinical Epidemiology 2012, 4:49-50

Published Date: 20 December 2012

Corrigendum

De Caterina AR, Harper AR, Cuculi F

Vascular Health and Risk Management 2012, 8:443-445

Published Date: 19 July 2012

A patient with mexiletine-related psychosis

Shailesh F, Singla S, Sureddi R, Deshmukh AJ, Paydak H

International Journal of General Medicine 2011, 4:765-766

Published Date: 2 November 2011

Metabolic pathway and distribution of superparamagnetic iron oxide nanoparticles: in vivo study

Schlachter EK, Widmer HR, Bregy A, Lönnfors-Weitzel T, Vajtai I, Corazza N, Bernau VJP, Weitzel T, Mordasini P, Slotboom J, Herrmann G, Bogni S, Hofmann H, Frenz M, Reinert M

International Journal of Nanomedicine 2011, 6:1793-1800

Published Date: 26 August 2011

Antioxidative fullerol promotes osteogenesis of human adipose-derived stem cells

Yang XL, Li CJ, Wan YP, Smith P, Shang GW, Cui Q

International Journal of Nanomedicine 2014, 9:4023-4031

Published Date: 20 August 2014